Scopio Labs has received an extra $10 million from Viola Growth. This money will help the company speed up the launch of its new product called the Complete Blood Morphology (CBM) analyzer.
The CBM analyzer uses AI to help automate one of the most time-consuming tasks in blood testing. With this new funding, Scopio’s Series D investment round now totals $52 million.
Scopio Labs says its CBM analyzer can automatically examine peripheral blood smears (PBS), a task that is still mostly done by hand in labs. While other tests, such as Complete Blood Counts (CBCs), have been automated for years, PBS reviews are still slow, vary from person to person, and require highly trained staff. This has become an even bigger problem because there aren’t enough lab professionals, and the demand for medical testing is growing.
“Our vision is to be the first to close the automation gap in hematology by developing a fully integrated and automated hematology process from CBC to final result,” said Itai Hayut, CEO and Co-founder at Scopio Labs. “This isn’t just a small step forward; it could potentially reshape the whole market by changing the workflow, the economics, and creating an entirely new market category. With CBM, the market can evolve from current digital lab solutions that help people make decisions to a system that’s designed to deliver fully automated results with the goal of eliminating the need for routine human morphology review. Beyond that, we also believe that this technology will pave the way to developing accurate and consistent morphology-based biomarkers and diagnostic panels, which can be used for early detection and monitoring of disease directly from blood.”
The CBM system uses advanced imaging and AI to look at 10 times more blood cells than older methods. This helps make the process more accurate and consistent.
Scopio says that labs already using its Full-Field PBS platform will be able to switch to the CBM system more easily once it’s ready.
Scopio Labs has received approval in both Europe (CE) and the U.S. (FDA) for its digital tools used to analyze blood smears and bone marrow samples. However, the CBM system is still under development and hasn’t been approved for medical use yet. The company plans to show the new analyzer at the ADLM 2025 Conference in Chicago later this month.
“We’re excited to join Scopio on their journey to reshape the future of hematology diagnostics,” added Igal Shany, General Partner at Viola Growth. “Scopio’s CBM analyzer represents a major leap forward for hematology labs, delivering autonomous morphology review with the depth, speed, and scalability this critical step urgently needs.”
Read more- Roast Foods Raises Investment to Expand Healthy Snacks Globally
